Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. The company's lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone818-661-6302
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings DateN/A
OptionableNot Optionable
Inspyr Therapeutics (OTCMKTS:NSPX) Frequently Asked Questions
What is Inspyr Therapeutics' stock symbol?
Inspyr Therapeutics trades on the OTCMKTS under the ticker symbol "NSPX."
How were Inspyr Therapeutics' earnings last quarter?
Has Inspyr Therapeutics been receiving favorable news coverage?
News coverage about NSPX stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inspyr Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Inspyr Therapeutics.
Who are some of Inspyr Therapeutics' key competitors?
Some companies that are related to Inspyr Therapeutics include Orexigen Therapeutics (OREXQ), Propanc Biopharma (PPCB), 89bio (ETNB), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM) and Immune Therapeutics (IMUN).
What other stocks do shareholders of Inspyr Therapeutics own?
Who are Inspyr Therapeutics' key executives?
Inspyr Therapeutics' management team includes the folowing people:
- Mr. Christopher P. Lowe, CEO, CFO, Pres, Principal Accounting Officer & Exec. Director (Age 48)
- Dr. John T. Isaacs, Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor
- Dr. Samuel R. Denmeade, Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board
How do I buy shares of Inspyr Therapeutics?
Shares of NSPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Inspyr Therapeutics' stock price today?
One share of NSPX stock can currently be purchased for approximately $0.00.
How big of a company is Inspyr Therapeutics?
What is Inspyr Therapeutics' official website?
How can I contact Inspyr Therapeutics?
Inspyr Therapeutics' mailing address is 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362. The company can be reached via phone at 818-661-6302 or via email at [email protected]
MarketBeat Community Rating for Inspyr Therapeutics (OTCMKTS NSPX)
MarketBeat's community ratings are surveys of what our community members think about Inspyr Therapeutics and other stocks. Vote "Outperform" if you believe NSPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
